2020
DOI: 10.1089/jop.2019.0075
|View full text |Cite
|
Sign up to set email alerts
|

Long-Term Efficacy of Intravitreal Conbercept Injection in the Treatment of Idiopathic Choroidal Neovascularization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 24 publications
0
3
0
Order By: Relevance
“…A 1-year follow-up study verified that the standard conbercept therapy strategy was safe and effective in patients over 50 years of age with mCNV, but the patients with greater central macular thickness had a high risk of recurrence [22]. Wu et al [23] reported that conbercept administered intravitreously (0.5 mg) with the 1 + PRN regimen was effective in treating iCNV during 44.59 ± 8.60 months of follow-up, but 7 of the 27 patients experienced CNV recurrence in their study, and the recurrence time varied. In a 48-month follow-up study of ranibizumab in mCNV, Tan et al [24] reported that the mean total number of injections was 4.0 ± 2.9 and 10% of patients experienced recurrence.…”
Section: Discussionmentioning
confidence: 99%
“…A 1-year follow-up study verified that the standard conbercept therapy strategy was safe and effective in patients over 50 years of age with mCNV, but the patients with greater central macular thickness had a high risk of recurrence [22]. Wu et al [23] reported that conbercept administered intravitreously (0.5 mg) with the 1 + PRN regimen was effective in treating iCNV during 44.59 ± 8.60 months of follow-up, but 7 of the 27 patients experienced CNV recurrence in their study, and the recurrence time varied. In a 48-month follow-up study of ranibizumab in mCNV, Tan et al [24] reported that the mean total number of injections was 4.0 ± 2.9 and 10% of patients experienced recurrence.…”
Section: Discussionmentioning
confidence: 99%
“…Intravitreal injections of anti-VEGF drugs may can inhibit the normal protective effect of VEGF on nerves and cause neuroretinal damage. Few reports to date have described the effects of intravitreal injections of conbercept in patients with ICNV [ 12 , 13 ].…”
Section: Introductionmentioning
confidence: 99%
“…Studies have attempted to evaluate the efficacy of several treatment modalities in iCNV, including photodynamic therapy,[ 2 3 ] bevacizumab,[ 4 ] ranibizumab,[ 5 6 ] and conbercept. [ 7 ] Some of these studies have also evaluated the long-term outcomes of treatment, and the efficacy of anti-VEGF agents offers a promising therapeutic modality.…”
Section: Introductionmentioning
confidence: 99%